(19)
(11) EP 1 077 721 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
20.06.2007 Bulletin 2007/25

(45) Mention of the grant of the patent:
02.05.2007 Bulletin 2007/18

(21) Application number: 99924258.9

(22) Date of filing: 14.05.1999
(51) International Patent Classification (IPC): 
A61K 39/385(2006.01)
C07K 7/08(2006.01)
C07K 7/06(2006.01)
(86) International application number:
PCT/US1999/010751
(87) International publication number:
WO 1999/059631 (25.11.1999 Gazette 1999/47)

(54)

PREVENTION AND TREATMENT OF HYPERGASTRINEMIA

VORBEUGUNG UND BEHANDLUNG VON HYPERGASTRINEMIE

PREVENTION ET TRAITEMENT DE L'HYPERGASTRINEMIE


(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

(30) Priority: 15.05.1998 US 85714 P

(43) Date of publication of application:
28.02.2001 Bulletin 2001/09

(60) Divisional application:
07008760.6
07008761.4

(73) Proprietor: Receptor Biologix, Inc.
Palo Alto, California 94303 (US)

(72) Inventors:
  • GEVAS, Philip, C.
    Key Biscayne, FL 33149 (US)
  • GRIMES, Stephen
    Davis, CA 95616 (US)
  • KARR, Stephen
    Davis, CA 95616 (US)
  • MICHAELI, Dov
    Larkspur, CA 94939 (US)
  • WATSON, Susan
    Edwalton, Nottingham NG2 6RB (GB)

(74) Representative: Manaton, Ross Timothy et al
Bromhead Johnson 19 Buckingham Street
London WC2N 6EF
London WC2N 6EF (GB)


(56) References cited: : 
WO-A-97/28821
US-A- 5 468 494
US-A- 5 609 870
US-A- 5 023 077
US-A- 5 607 676
US-A- 5 622 702
   
  • WATSON SUSAN A ET AL: "Pre-clinical evaluation of the gastrimmune immunogen alone and in combination with 5-fluorouracil/leucovorin in a rat colorectal cancer model." INTERNATIONAL JOURNAL OF CANCER, vol. 75, no. 6, 16 March 1998 (1998-03-16), pages 873-877, XP002194963 ISSN: 0020-7136
  • SUMII MASAHARU ET AL: "Regulation of antral peptides by administration of omeprazole to healthy men." AMERICAN JOURNAL OF GASTROENTEROLOGY, vol. 89, no. 11, 1994, pages 2033-2037, XP001068668 ISSN: 0002-9270
  • MCCLOY R F ET AL: "Pathophysiological effects of long-term acid suppression in man." DIGESTIVE DISEASES AND SCIENCES, vol. 40, no. 2 SUPPL., 1995, pages 96S-120S, XP001068385 ISSN: 0163-2116
  • FRESTON JAMES W: "Long-term acid control and proton pump inhibitors: Interactions and safety issues in perspective." AMERICAN JOURNAL OF GASTROENTEROLOGY, vol. 92, no. 4 SUPPL., 1997, pages 51S-57S, XP001068667 ISSN: 0002-9270
  • REGULATORY PEPTIDES THORNDYKE M.: 'Identification and localization of material with gastrin-like immunoreactivity in the neutral ganglion of a photochordate, Ciona intestinalis' vol. 16, 1986, pages 269 - 279, XP002921542.
  • CANCER RESEARCH WATSON ET AL: 'Gastrimmune Raises Antibodies that Neutralize Amidated and Glycine extended Gastrin-17 and inhibit the growth of colon cancer' vol. 56, 1996, pages 880 - 885, XP002921543.
  • INT. J. CANCER WATSON ET AL: 'Anti-gastrin antibodies raised by gastrimmune inhibit growth of the human colorectal tumor AP5' vol. 61, 1995, pages 233 - 240, XP000654518.
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).